Chronic Hepatitis-C. Chronic viral hepatitis C
Conditions
Interventions
Intervention group: Sofosbuvir 400 mg + Velpatasvir 100 mg once daily for 12 weeks.
Sponsors
Hilton Pharma Pvt Ltd
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Subjects willing to undergo screening and sign informed consent Male or female outpatients =18 years of age Serologically and histologically proven CHC, detectable HCV RNA, elevated ALT, and compensated liver disease.
Exclusion criteria
Exclusion criteria: Unable to give written informed consent Pregnant and/or Nursing Women Contraindicated to medicine or any of the component of prescribed therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained Virologic Response (SVR). Timepoint: Assessed at week 24 from the baseline visit or start of therapy. Method of measurement: HCV-RNA PCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| End of Treatment Response (ETR). Timepoint: assessed at week 12 from baseline visit or start of therapy. Method of measurement: HCV-RNA PCR.;Adverse Events or Serious Adverse Events. Timepoint: assessed at week 04, week 12 & week 24 follow-up visits. Method of measurement: Clinical examination or history by study participants. | — |
Countries
Pakistan
Contacts
Public ContactDr. Nazish Butt
Jinnah Post graduate Medical Center
Outcome results
None listed